Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20
Advertisement

Related Content

Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Medtronic R&D Spending Shifts To Neuromodulation, Diabetes
Medtronic R&D Spending Shifts To Neuromodulation, Diabetes
Medtronic Enters Into FDA Consent Decree Over Physio-Control Quality Issues
Earnings In Brief
Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude
Endeavor drug-eluting stent approved
Hospital Suppliers Show Vigor In ’07, With Prospects Strong For ’08 – Index
Medtronic Taps Into Expanded Spinal Market With $3.9 Billion Kyphon Deal
Advertisement
UsernamePublicRestriction

Register

MT026146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel